课题基金 / 基金详情

OTHER FUNCTIONS SILOAM"PHASE I, TOPIC 309, LOW VOLUME, ULTRA-SENSITIVE IMMUNODIA

OTHER FUNCTIONS SILOAM"PHASE I, TOPIC 309, LOW VOLUME, ULTRA-SENSITIVE IMMUNODIA
其他功能 SILOAM”第一期,主题 309,低容量,超灵敏免疫
批准号:
8566207
负责人:
金额:
$19.86万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-09-28 至 2013-06-27

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
SBIR项目的目标是开发一种低损失、超灵敏的免疫诊断系统,用于用少量样品快速测量多种癌症生物标志物。该系统可以帮助医生提高癌症的早期发现、诊断、预后和治疗监测。
英文摘要
The goal of this SBIR project is to develop a low lost, ultrasensitive immunodiagnostic system for measuring multiple cancer biomarkers rapidly with small amount of samples. This system can be used by physicians to improve cancer early detection, diagnosis, prognosis and treatment monitoring. Cancer biomarkers have been widely used for cancer early detection and diagnosis. Assay with multiple cancer biomarkers can significantly increase the sensitivity and specificity. Current detection platforms are limited in multiple ways to effectively address those needs. Instruments that are fast, can work with low sample volumes are typically expensive and have limited sensitivity. Ultra-high sensitivity platforms are also expensive and typically require complex sample prep steps and large sample volumes. Siloam has developed a novel ¿Optimiser¿ microfluidic assay platform, for meauring multiple analytes with 20x sensitivity, 20x less sample and reagent consumption and total assay times less than 20 minutes. Use of this technology allows for limited automation system to operate as a fully automated immunodiagnostic analyzer. Cancer is the leading cause of deaths worldwide. 571,950 deaths from cancer are projected to occur in US in the 2011. The Immunodiagnostic system can help in early cancer detection and diagnosis and directly contribute to reduced mortality/healthcare burden.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金